Purchase this article with an account.
Martina T Kralinger, Claus Zehetner, Inga Waltl, Rudolf Kirchmayr, Gerhard F. Kieselbach; VEGF Plasma levels after intravitreal injection of aflibercept and ranibizumab. Invest. Ophthalmol. Vis. Sci. 2014;55(13):4965.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To determine the level of vascular endothelial growth factor (VEGF) in patients with exudative macular degeneration before and after intravitreal injection of aflibercept and ranibizumab.
A total of 25 patients with exudative AMD were identified for enrollment in this prospective, randomized, controlled study. Fifteen of these patients were treated with intravitreal aflibercept (2mg) while 10 patients received ranibizumab (0,5mg). Blood samples were obtained before intravitreal injection and two and four weeks after injection. The concentration of the plasma samples was measured by ELISA.
The VEGF levels in patients treated with ranibizumab did not change significantly from baseline 91.3±59.9 (range 15-217) pg/ml to 135.5±133.3 (range 10-473) pg/ml at 7 days and 77.1±46.6 (range 43-178) pg/ml at 4 weeks of follow-up. One week after injection of aflibercept a decrease from baseline VEGF plasma levels ranging between 35 and 58pg/ml below 9 pg/ml was observed in all samples. At four weeks an increase to 20 and 51 pg/ml occurred in two patients while in the other 3 patients the VEGF levels remained below 9pg/ml. Final statistical analyses will be done after analyses of the residual 30 samples of the aflibercept group that is in progress currently.
So far our results are in agreement with the data presented by Avery at the ASRS in Toronto this year showing a reduction of plasma levels after aflibercept while no systemic effect of ranibizumab was observed.
This PDF is available to Subscribers Only